In 2024 I shared a poem in JAMA Onc on giving bad news & the pain of loss when a child dies. It's the worst part of my job.

Cutting research & global aid funding + firing scientists, clinicians, & public health professionals = more children die.

Our leaders have my patients' blood on their hands.

Orca-Q Shows Promise in High-Risk Hematologic Cancers and BFT Conditioning May Synergize With the Agent One-year follow-up data from an ongoing phase 1 study showed that Orca-Q offered similar benefits as T-cell depletion, without the typical compromises seen.

Orca-Q Shows Promise in High-Risk Hematologic Cancers and BFT Conditioning May Synergize With the Agent @cityofhope.bsky.social @astct.bsky.social #TANDEM25 #hematology #oncology
www.onclive.com/view/orca-q-...

Axatilimab Displays Durable Responses in cGVHD Irrespective of Number of Prior Lines of Treatment Axatilimab displayed similar efficacy regardless of the number of prior lines of therapy in chronic graft-versus-host disease.

Axatilimab Displays Durable Responses in cGVHD Irrespective of Number of Prior Lines of Treatment @astct.bsky.social #TANDEM25 #hematology #oncology #GVHD
www.onclive.com/view/axatili...

Orca-T Is a Safe Addition to HSCT-RIC in Advanced Hematologic Malignancies Orca-T with HSCT-RIC displayed robust and early donor myeloid and T-cell engraftment in patients with advanced hematologic malignancies.

Orca-T Is a Safe Addition to HSCT-RIC in Advanced Hematologic Malignancies
@astct.bsky.social #TANDEM25 #heme #oncology
www.onclive.com/view/orca-t-...

We are still hiring for the Sarah Cannon Transplant and Cellular Therapy Network - pls reach out to me if you are attending #Tandem25

How to publish a scientific manuscript in a high-impact journal

Open Access
www.sciencedirect.com/science/arti...

UnitedHealth Is Sick of Everyone Complaining About Its Claim Denials Two months after UnitedHealthcare CEO Brian Thompson was killed, the insurer's parent company is going after people who say it denies too many claims.

Lol. Lmao, even www.rollingstone.com/culture/cult...

Coming 🔜 @astct.bsky.social Mobile APP 2.0. New design, new features & enhanced GVHD calculator - trying out the beta version on my way to #Tandem25. Will update once we launch #medsky #bmtsm #CARTcells #geneRx

#tandem25 #bmtsm Arnhold: Ruxolitinib protects from IFNg mediated damage but doesn’t antagonize negative effects of steroids on epithelial regeneration, latter mediated by STAT3 signaling.

#tandem25 #bmtsm Arnhold: IL22 promotes gut epithelial regeneration even in the presence of corticosteroids.

Glad to see @astct.bsky.social @cibmtr.bsky.social making a statement about the value and importance of NIH funding #Tandem25

#tandem25 #bmtsm Maas-Bauer: ROCK1 (isoform of ROCK2, target of Belumosudil) is most differentially upregulated kinase in non-responders to aGVHD therapy. ROCK1/2 inhibition reduces aGVHD in mouse model of major MHC mismatch allo. Assoc w reduction of CD11b+ cells in gut.

#tandem25 #bmtsm Maas-Bauer: ROCK1/2 inhibition of monocyte/macrophage and DCs ameliorates aGVHD, but does not (completely) antagonize tumor cell killing (in vitro and in vivo models).

#tandem25 #bmtsm Maas-Bauer: ROCK1/2 inhibition and JAK inhibition have synergistic effects (!). Belumosudil has yet to be studied clinically in SR-aGVHD.

ASTCT 2025 APP Diana Velez and our great nursing staff at Sarah Cannon Methodist San Antonio presenting on late neuro tox in CART

#tandem25 #bmtsm Maas-Bauer: ROCK1/2 inhibition downregulate NFkB signaling assoc with inflammation and upreg of anti-inflammatory IL10 — basically modulating n of monocyte phenotype to antiinflammatory M2 type. Decreased F-actin in ROCK1/2i treated is assoc with deceased monocyte migration.

Are you at #Tandem25? Visit booth 340 to learn more about Sarah Cannon Transplant and Cellular Therapy Network - the largest provider of transplantation and cellular therapy in the US. And yes, we are hiring for several positions including physicians, PharmDs, nurses, and more.

ASTCT 2025 APP Diana Velez and our great nursing staff at Sarah Cannon Methodist San Antonio presenting on late neuro tox in CART

In addition to the potential to impact individual outcomes of those patients we serve, physician leadership is needed now more than ever to address the gaps in our system of healthcare

We are hiring to add to our 60+ leukemia/cell therapy/BMT physicians across the Sarah Cannon Transplant and Cellular Therapy Network - pls direct message me to learn more about opportunities for clinical investigators and clinicians 🙏

Bilateral gene therapy in children with autosomal recessive deafness 9: single-arm trial results

"All patients had bilateral hearing restoration."

Open Access
www.nature.com/articles/s41...

4. How to Pick a Graduate Advisor

Thanks💐 @richardhuskey.bsky.social

Open access
www.cell.com/neuron/pdf/S...

Three must read papers for PhD students. #scisky #PhD #science #research #academicsky

1. The importance of stupidity in scientific research

Open Access
journals.biologists.com/jcs/article/...

Heating Up IDH-Mutant Gliomas | NEJM A recent study unpicks a key immune-mediated mechanism of mutant IDH–blocking drugs such as vorasidenib in the treatment of IDH-mutant glioma.

A recent study unpicks a key immune-mediated mechanism of mutant IDH–blocking drugs such as vorasidenib in the treatment of IDH-mutant glioma. Learn more in a new Clinical Implications of Basic Research article: nej.md/4f3dIMf

#MedSky

We had alpacas 🦙🦙 at the @astct.bsky.social @cibmtr.bsky.social #Tandem24 - beat that #ASH24 @ash-hematology.bsky.social 😜

Wait, wait, wait, Emergency, you're going to want to hear this. In the latest video in our partnership with @drglaucomflecken, ENT explains findings from a recent trial looking at pomalidomide as a tr... TikTok video by NEJM

Watch the latest video in our partnership with @glaucomflecken.bsky.social, which explains the results of the PATH-HHT trial: www.tiktok.com/@nejm.org/vi...

Just publish paper evaluating effects of vaccination on long COVID risks in children/adolescents during Delta/Omicron periods

We found vaccines strongly protected against long COVID-19, and the effect was almost wholly mediated by reduced infection risk

www.sciencedirect.com/science/arti...

Why I stay on social media and why I will never stop posting about iron deficiency.

Every year this is how I feel after ASH. A final #ASHaiku

Every year it comes
ASH conference lights the path
Purpose renewed

#ASH24 #hematology #HemeSky #lymsm

This is why I'm constantly urging people to get screened. It's so important. Iron infusions were life changing for me #nurse